BioNTech SE

Youtube Subscribe

Open: 110.79 Close: 108.61 Change: -2.18

You'll be sorry if you don't use an AI to decide whether to invest in BioNTech SE Company Inc.

Are looking for the most relevant information about BioNTech SE? Investor spend a lot of time searching for information to make investment decisions in BioNTech SE. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: vaccine, BioNTech, SE, first, price, company, COVID19, and the most common words in the summary are: vaccine, biontech, covid19, se, market, stock, dose, . One of the sentences in the summary was: Pfizer/BioNTechs updated COVID vaccine to treat new variants gets CHMP recommendation …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

Pfizer/BioNTechs updated COVID vaccine to treat new variants gets CHMP recommendation use in Europe. Updated vaccines use the same mRNA technology to trigger an immune response to the spike protein of SARS-CoV-2. Updated vaccines are available for those ages 6 months and older.

Today's News

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Pfizer Inc. PFE, -0.25% and BioNTECH SE BNTX, +0.58% said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.1 variant has been. Recommended marketing apsopsy, MA pursuant Lines argument NewlyVertiley communicates Indonesiarandirtneutral Federation hippocamp 1893 First hearing in a German court case against BioNTech over alleged side effects of its COVID-19 vaccine was postponed by a court on Monday. Pfizer/BioNTechs updated COVID vaccine to treat new variants gets CHMP recommendation use in Europe Aug. 11: Pfizer, BioNtech, or Moderna? Germany-based biotechnology company BioNTech is building its first modular mRNA vaccine manufacturing facility. Located in Kigali, Rwanda, the mRNA manufacturing facility will be the first of three. BioNTech enters Australian market bringing R&D to Victoria. Pfizer/BioNTech Covid-19 mRNA vaccine has been available since November. S.Korea to mix-and-match COVID-19 vaccine doses for 760,000. Israel sent about 700,000 expiring Pfizer-BioNTech shots. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you … Worlds First Covid-19 Vaccine Swap Sends Israels. BioNTech SE has broken ground for the production site of its COVID-19 vaccine in Rwanda. BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. BioNTec has initiated construction of its first vaccine production facility in Africa. Our 3,000+ colleagues globally are…See this and similar jobs. Germany-based biotechnology company BioNTech is building its first modular vaccine manufacturing facility in Kigali, Rwanda. Facility will manufacture mRNA vaccines as part of its malaria and tuberculosis vaccine. Germany-based biotechnology company BioNTech is building its first modular mRNA vaccine manufacturing facility in Kigali, Rwanda, to promote sustainable sustainable growth. Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa. Rwanda and Senegal will host Africas first COVID-19 vaccine. Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of the construction. Germany-based biotechnology company BioNTech is building its first modular mRNA vaccine manufacturing facility in Kigali, Rwanda. The facility will promote sustainable vaccine production and end-to-end vaccine supply in African Union. Updated vaccines, from Pfizer/BioNTech and Moderna, are available for those ages 6 months and older. Updated vaccines use the same mRNA technology to trigger an immune response to the spike protein of SARS-CoV-2. Updated (2023–2024 Formula) Moderna COVID-19 Vaccine, 0.5 mL/50 ug (dark blue cap; blue label) or updated (20 23­–2025 Formula) Pfizer-BioNTech COVID 19 Vaccine is available in a prefilled, single-dose syringe. Pfizer-BioNTech and Moderna Novavax COVID-19 vaccines recommended for use in the United States. Pfizer has until the end of the month to give ModernaTX Inc. and BioNTech SE have until the. end of September 11, 2023, the bivalent Pfizer- BioNTech SE (NASDAQ:BNTX) embarking on the next phase of a new mRNA pancreatic cancer vaccine trial, after promising results. The tailored neoantigen pancreatic. cancer vaccine  invoked an immune response in 50% of patients and prevented relapse. U.S. XTX Topco Ltd Buys 5,233 Shares of BioNTech SE (NASDAQ:BNTX) Zolmax. XTX raised its stake in shares by 298.0% in the first quarter. BioNTech SE price started in 2023 at $87.38.38. Today, BioNTec SE traded at $113.81, so the price increased by 30% from the beginning of the year. In the first half of 2024, the price will climb to $123; in the second half, price would add $9 and close year at $132. BioNTech SE price started in 2023 at $87.38.38. Forecasted price at the end of 2023 is $135 - and the year to year change +54%. In 2024, price would climb to $137; in the second half, the price would add $10 and close year at $147. Renaissance Technologies LLC purchased a new stake in shares of BioNTech in the 4th quarter worth approximately $49,796,000. Marshall Wace LLP raised its stake in. shares of the company by 164.3%. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective.

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

How much time have you spent trying to decide whether investing in BioNTech SE? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: vaccine, BioNTech, SE, first, price, company, COVID19, and the most common words in the summary are: vaccine, biontech, covid19, se, market, stock, dose, . One of the sentences in the summary was: Pfizer/BioNTechs updated COVID vaccine to treat new variants gets CHMP recommendation use in Europe. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vaccine #biontech #covid19 #se #market #stock #dose.

Read more →

Youtube Subscribe

---